लोड हो रहा है...
CBIO-15. MDM2 INHIBITOR SYNERGY WITH BCL-XL INHIBITION FOR p53 WILD TYPE GLIOBLASTOMA
BACKGROUND: Glioblastoma (GBM) is an infiltrative, uniformly fatal brain tumor, treated with surgery, radiation, and Temozolomide (TMZ). Chemoradiation induces a senescent-like phenotype, which contributes to disease recurrence. We recently found that, radiated GBM cells can be eliminated by inhibit...
में बचाया:
| में प्रकाशित: | Neuro Oncol |
|---|---|
| मुख्य लेखकों: | , , , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Oxford University Press
2020
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7650374/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.075 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|